Alliance for Clinical Trials in Oncology
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection
- First Posted Date
- 2019-04-25
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 534
- Registration Number
- NCT03927027
- Locations
- 🇺🇸
Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States
Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 521
- Registration Number
- NCT03870633
- Locations
- 🇺🇸
Heartland Regional Medical Center, Saint Joseph, Missouri, United States
🇺🇸Sanford Bismarck Medical Center, Bismarck, North Dakota, United States
🇺🇸Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-28
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 325
- Registration Number
- NCT03857620
- Locations
- 🇺🇸
Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
🇺🇸Fairview Southdale Hospital, Edina, Minnesota, United States
🇺🇸Marshfield Medical Center-Rice Lake, Rice Lake, Wisconsin, United States
Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 39
- Registration Number
- NCT03839940
- Locations
- 🇺🇸
Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
🇺🇸Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
🇺🇸Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States
Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 627
- Registration Number
- NCT03766009
- Locations
- 🇺🇸
Epic Care-Dublin, Dublin, California, United States
🇺🇸Bay Area Breast Surgeons Inc, Emeryville, California, United States
🇺🇸Contra Costa Regional Medical Center, Martinez, California, United States
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT03633331
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
🇺🇸Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Kootenai Cancer Center, Post Falls, Idaho, United States
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 271
- Registration Number
- NCT03609216
- Locations
- 🇺🇸
Mary Bird Perkins Cancer Center - Metairie, Metairie, Louisiana, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 18
- Registration Number
- NCT03609021
- Locations
- 🇺🇸
Mount Carmel East Hospital, Columbus, Ohio, United States
🇺🇸Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
- First Posted Date
- 2018-07-05
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 690
- Registration Number
- NCT03578081
- Locations
- 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸Hurley Medical Center, Flint, Michigan, United States
🇺🇸Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 897
- Registration Number
- NCT03414970
- Locations
- 🇺🇸
Central Maryland Radiation Oncology in Howard County, Columbia, Maryland, United States
🇺🇸Dublin Methodist Hospital, Dublin, Ohio, United States
🇺🇸Doctors Hospital, Columbus, Ohio, United States